Cencora is one of the largest pharmaceutical distributors in the world. It sits in the middle of the medicine supply chain, connecting drug manufacturers to hospitals, pharmacies, doctors, and nursing homes. Every time a pharmacy fills a prescription or a hospital orders cancer drugs, Cencora likely handled the logistics. The company earns a small fee on each transaction, which adds up fast when you are moving roughly one in five prescription drugs sold in America. It also sells data services, packaging solutions, and consulting to the same customers it supplies. The diagram below traces where the money goes.
How Cencora Makes Money
flowchart TD
A["Healthcare Providers
Hospitals, Pharmacies, Clinics"] -->|"Orders pharmaceuticals"| B["U.S. Healthcare Solutions
Distribution Centers"]
C["Pharmaceutical Manufacturers
Brand, Generic, Biotech"] -->|"Supply products"| B
B -->|"$321.3B revenue, 3.6% gross margin"| D["Product & Service Sales
Prescription Drugs, Specialty Products"]
D -->|"$3.9B operating cash flow"| E["Value-Added Services
Generic programs, Pharmacy automation, Data analytics, Consulting"]
E -->|"Higher-margin adjacencies"| F["International Healthcare Solutions
Europe, Canada, Logistics, Regulatory Services"]
F -->|"Global reach, expanded margins"| D
E -->|"Customer efficiency gains"| A
A -->|"Increased loyalty, volume growth"| B
B -->|"Investment in warehouse automation, ERP systems, technology"| G["Operating Infrastructure
Distribution network, IT systems, Supply chain security"]
G -->|"Lower operating costs, scale"| B
D -->|"$3.2B free cash flow"| H["Growth Investments
Acquisitions, Technology, New service lines"]
H -->|"RCA acquisition $4.0B, specialty pharma expansion"| A
Five years of financial data tell a consistent story: Cencora is a high-volume, low-margin business that keeps growing. Revenue has climbed every single year, from $214.0 billion in fiscal 2021 to $321.3 billion in fiscal 2025. That is roughly 50% growth in five years. The engine behind recent gains includes specialty drugs, especially GLP-1 medicines used for diabetes and weight loss, which grew by $7.7 billion in fiscal 2025 alone.
Cencora Annual Revenue ($ Billions)
Revenue has grown every year for five consecutive years, reaching $321.3 billion in fiscal 2025.
Revenue growth is impressive, but the gross margin tells a different story. Cencora keeps only about 3.5 cents of gross profit for every dollar of revenue it collects. That number has barely moved in five years, staying in a narrow band between 3.2% and 3.6%. This is the nature of pharmaceutical distribution: the company processes enormous sums of money but retains only a sliver of each transaction. The real test of financial health here is not margin expansion but cash generation.
Why Margins Are So Thin in Drug Distribution
Drug distributors do not make the medicines they sell. They warehouse and ship products made by pharmaceutical companies to healthcare providers. Because they add logistical rather than manufacturing value, and because they compete hard against McKesson and Cardinal Health, pricing power is limited. A 3% gross margin on $321 billion in revenue still produces billions of dollars in gross profit, but there is little room for error.
Free cash flow, which is the cash left over after the company pays for its operations and capital spending, has held up well. It was $2.2 billion in both 2021 and 2022, then jumped to $3.5 billion in 2023, before settling at $3.0 billion in 2024 and $3.2 billion in 2025. That consistency matters because it funds acquisitions, debt repayment, and shareholder returns without relying on borrowing.
$3.2B
Free cash flow in fiscal 2025, after years of heavy acquisition spending including the $4.0 billion purchase of Retina Consultants of America
Debt has fluctuated with the acquisition cycle. Net debt fell from $4.1 billion in 2021 to $1.3 billion in 2024, showing real paydown discipline. Then it rose again to $3.3 billion in 2025, driven by new borrowings to fund the Retina Consultants of America deal. That acquisition added an 85% stake in a specialty retinal care provider for $4.042 billion in cash, plus contingent payments. The logic is to move further into high-margin specialty medicine, where profits per transaction are thicker than in general pharmaceutical distribution.
2025
milestone
Cencora Acquires Retina Consultants of America
In January 2025, Cencora paid $4.042 billion in cash for an 85% stake in Retina Consultants of America. This moved the company beyond pure distribution into direct involvement with specialty physician practices. The U.S. Healthcare Solutions segment saw gross profit rise 23.1% in fiscal 2025, with RCA as a key contributor. The move signals a deliberate push into higher-margin clinical relationships, but it also added significant new debt and ongoing contingent payments.
The risks facing Cencora are specific and serious. The most pressing is customer concentration. Walgreens and Boots together made up approximately 25% of revenue in fiscal 2025. That is an enormous dependence on a single customer relationship. Walgreens was acquired by a private equity firm in August 2025 and has announced plans to close about 1,200 stores. If those closures reduce the volume of drugs flowing through Walgreens locations, or if the new owners renegotiate distribution terms, Cencora's revenue base shrinks.
25%
Share of Cencora's total fiscal 2025 revenue attributable to Walgreens and Boots combined
Government pricing policy is the second major risk. Multiple new laws and executive orders, including the Inflation Reduction Act and Executive Order 14297 on drug pricing, could change how drugs are priced and distributed. If government programs shift toward direct purchasing that bypasses traditional wholesalers, or if price controls reduce the value of drugs moving through the supply chain, Cencora's transaction fees shrink. Tariffs add another layer of pressure. Proposed tariffs on pharmaceutical imports, packaging materials, and goods from India and Brazil could raise costs without a corresponding ability to pass them on.
What a Drug Pricing Policy Change Could Mean for Distributors
Cencora charges fees tied to the value and volume of drugs it moves. If government policy reduces drug prices or allows patients to buy directly from manufacturers, less revenue flows through distributors. The company does not set drug prices, so it cannot offset this by charging more. Its only lever is volume.
Cybersecurity is also a documented vulnerability. Cencora experienced a data breach in February 2024 where information was taken from its systems, and another event in March 2023. The company handles sensitive health data for tens of millions of patients. A serious ransomware attack could shut down distribution operations and expose the company to lawsuits. Finally, the legacy of opioid litigation has not fully closed. While the major $26 billion settlement across 46 states was agreed in 2022, opioid-related legal fees still appeared in fiscal 2025 expenses.
Goodwill impairments of $723.9 million in fiscal 2025 and $418.0 million in fiscal 2024 were both tied to PharmaLex, the specialized consulting business acquired in 2023. Two consecutive write-downs on the same acquisition is a quiet signal that the deal has not performed as expected.
Cencora is now exploring strategic alternatives for several businesses, including MWI Animal Health and parts of PharmaLex. That means it may sell or restructure those units. The outcome of those decisions will shape how much capital the company has available for its core pharmaceutical distribution and specialty medicine strategy.
The Bet
Cencora's financial logic depends on pharmaceutical volume continuing to grow and flowing through traditional distributors rather than being routed around them. The U.S. pharmaceutical market is projected to grow at about 8.4% per year through 2029, driven by an aging population, new specialty drugs, and expanded use of GLP-1 medicines. If that volume growth materializes and government policy does not redirect drug purchasing away from wholesalers, Cencora's massive scale becomes a durable advantage. If drug pricing reform reduces transaction values, or if large customers like Walgreens contract significantly, the volume growth required to offset lower per-transaction economics may not arrive fast enough.
Open question
Cencora moves more than $321 billion in pharmaceutical products per year and generates reliable free cash flow. Its push into specialty medicine through Retina Consultants of America could lift margins above the thin 3.5% level that defines commodity distribution. But 25% of revenue depends on Walgreens, which is now owned by a private equity firm actively closing stores. And government drug pricing reform could restructure the economics of the entire supply chain. Can Cencora build enough specialty medicine revenue to stay resilient if Walgreens shrinks and drug pricing policy reduces what flows through traditional distributors?
Compiled · 10-K · FY2025
